# A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

> **NCT00491530** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 310 (actual)

## Conditions studied

- Mixed Dyslipidemia

## Interventions

- **DRUG:** ABT-335
- **DRUG:** rosuvastatin calcium
- **DRUG:** simvastatin
- **DRUG:** atorvastatin calcium

## Key facts

- **NCT ID:** NCT00491530
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2012-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00491530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00491530, "A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00491530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*